The role of stereotactic body radiotherapy in oligoprogressive breast cancer: A site-specific analysis of the prospective, phase-II RADIANT trial
Rattachement africain : ca, ie. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Background Standard-of-care management for patients with progressive metastatic breast cancer is changing systemic therapy lines. For patients with limited disease progression (‘oligoprogression'), there is interest in treating progressive sites with stereotactic body radiation therapy (SBRT) whilst maintaining the current systemic therapy. Here we report on the clinical, quality of life (QOL) and adverse event findings for a cohort of patients with oligoprogressive breast cancer enrolled on the prospective, phase-II RADIANT clinical trial. Methods RADIANT (NCT04122469) was a single-arm, phase-II basket trial which included patients with oligoprogressive metastatic breast cancer. Patients on systemic therapy for ≥ 3 months received SBRT over 1–5 fractions, targeting up to 5 metastases with radiographic progression. The primary endpoint was cumulative incidence of change in systemic therapy. Secondary endpoints included local control, progression-free survival, overall survival, adverse events and health-related (HR) QOL. Analysis by disease histology was planned a priori . Results Thirty patients were enrolled and analyzed; the median age was 60.0 years, 80% had invasive ductal carcinoma and 90% were estrogen-receptor (ER)-positive. Most patients had recurrent metastatic disease (63.3%), while 36.7% had de novo metastatic disease. Most patients were on first-line (66.7%) systemic therapy. Median follow-up time was 33.7 months (range 2.5–57.2 months). The cumulative incidence of change in systemic therapy at 1-year was 30.0% (95% CI, 17.2–52.4%) and at 2-years was 50.4% (95% CI, 34.9–72.8%). At 1-year, local control rate was 90.0% and distant control rate was 56.7%. There were no grade ≥ 3 adverse events attributable to SBRT. HRQOL was maintained throughout the follow-up period. Conclusion Among this cohort of patients with oligoprogressive breast cancer, SBRT is a safe and promising intervention, with potential to delay next-line systemic therapy. However, as a significant cohort of patients do require a change in systemic therapy within 1–2 years of SBRT, biomarkers are needed to best select patients who would benefit clearly from this approach.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- The role of stereotactic body radiotherapy in oligoprogressive breast cancer: A site-specific analysis of the prospective, phase-II RADIANT trial
- Date Crossref
- 01/07/2026
- Éditeur
- Elsevier BV
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University Health Network Princess Margaret Cancer Centre pays non établi dans la noticeÉtablissement de santé
-
University of Toronto Department of Radiation Oncology pays non établi dans la noticeUniversité ou école supérieure
-
Princess Margaret Cancer Centre pays non établi dans la noticeÉtablissement de santé
-
Western University Division of Radiation Oncology pays non établi dans la noticeUniversité ou école supérieure
-
London Health Sciences Centre pays non établi dans la noticeÉtablissement de santé
-
Occupational Cancer Research Centre pays non établi dans la noticeStructure de recherche
-
Cork University Hospital pays non établi dans la noticeÉtablissement de santé
-
St Michael’s Hospital pays non établi dans la noticeÉtablissement de santé
-
Verspeeten Family Cancer Centre pays non établi dans la noticeInstitution
-
University College Cork Radiation Oncology pays non établi dans la noticeUniversité ou école supérieure
-
St. Michael's Hospital Division of Oncology and Hematology pays non établi dans la noticeÉtablissement de santé
Princess Margaret Cancer Centre — University Health Network, Department of Radiation Oncology — University of Toronto et Princess Margaret Cancer Centre, avec 8 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.